A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy
in patients with metastatic or locally advanced breast cancer in order to estimate the
Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2
Dose (RP2D).